Dr. Jordan Metzl says sports medicine doctors will prescribe GLP-1s for arthritic knees within five years

The Ozempic era has now reached the knee. On The Ultimate Human, Dr. Jordan Metzl said that within five years, sports medicine doctors are going to be prescribing GLP-1 drugs for overweight patients with arthritic knees.

That is the kind of sentence that makes old-school orthopedics sound like it just wandered into a wellness conference wearing a knee brace. But Metzl’s point is not some soft-focus biohacker mush. It is brutally practical: if someone’s knee hurts because they are carrying too much weight, and they can’t lose weight because their knee hurts too much to move, the old advice, “just lose weight,” is basically a motivational poster stapled to a locked door.

because in my view five years from now sports medicine doctors are are going to be prescribing GLP1s for people in that category of overweight with arthritic knees because they’re so challenging and our old paradigm of just lose weight and your knee will feel better. Like, dude, I would if I could, but my knee hurts too much.

Metzl is not an influencer pretending to have discovered walking. He is a sports medicine physician at Hospital for Special Surgery, the kind of doctor who sees both the recreational runner with a cranky meniscus and the patient who has entered the medical doom loop of weight, pain, inactivity, more weight, more pain. His brand is exercise as medicine, and much of this appearance is him arguing that physicians should prescribe movement as seriously as they prescribe pills.

Which is why the GLP-1 claim lands harder. This is not a drug salesman dunking on lifestyle change. It is an exercise evangelist admitting that some people may need the drug to get back to the lifestyle change.

The knee pain trap has a new escape hatch

Metzl cites a study published in the New England Journal of Medicine, involving people with BMI over 30, moderate knee arthritis on X-ray, and symptoms that matched the imaging. One group received placebo. Another received a GLP-1. Everyone got diet and exercise advice. The results, as Metzl tells it, were not subtle.

The group that basically was given the placebo uh lost about 3% of weight. The group that that basically was given the GLP1 lost about 20% of their weight.

their knee pain reduced by about half and their their self-reported activity profile increased by about half compared to the placebo group.

This is the real clinical hinge. GLP-1s are usually talked about as weight-loss drugs, or diabetes drugs, or the reason every dinner party now includes one person explaining “food noise” like they are translating ancient runes. Metzl is framing them as mobility drugs, at least for a particular orthopedic patient. Less weight, less pain. Less pain, more movement. More movement, a better shot at health.

Is that a little tidy? Sure. Knee arthritis is not just a bathroom-scale problem. Cartilage, strength, inflammation, gait, muscle mass, access to care, all of it matters. And Metzl himself flags the obvious caveat, the long-term effects of these drugs are still being learned. He also notes the study was funded by Novo Nordisk, which is not disqualifying, but it does mean you don’t read it with your hands folded like a choirboy.

we don’t know the long-term effects of some of these peptides um like GLP1s and so there’s some question on that but we do know the long-term effects of chronic obesity which are really dangerous to people.

That is the most honest version of the argument. Not “miracle drug.” Not “lazy people’s shortcut.” More like: we know the current approach is failing a lot of patients, and we now have a tool that may help some of them move.

Metzl still wants your doctor to prescribe sweat

The rest of Metzl’s case is less surprising, but it explains why he is not simply hopping on the GLP-1 bandwagon. He wants medicine to stop waiting until the body breaks. He teaches future doctors at Cornell Medical School how to prescribe exercise. He runs free public fitness classes in New York. He talks about movement with the zeal of a man who arrived at a podcast sweaty because he literally biked there after a run.

His most Ringer-ready line is that if exercise were a pill, every doctor would be handing it out like Halloween candy.

if we had a drug that was 100% effective for almost every single chronic disease, it was basically 100% efficacious, worked for every single person around the world. rich or poor, young or old, had zero side effects and only positive effects. Everybody should be prescribing this medicine.

That claim is rhetorically juiced. Exercise does not work exactly the same way for every person, and “100% effective” is doing push-ups in a cape. But the broad direction is right: movement helps metabolic health, mood, strength, function, and aging better than almost anything else you can do without a co-pay. The problem is that knowing this has never been the same as doing it. Everyone knows the gym exists. The couch also exists, and it has snacks.

Metzl’s better insight is that motivation is not a moral quality. It is design. He talks about fun, community, prepaid trainers, walking groups, workout partners, anything that lowers what he calls “the cost to act.” This is where his GLP-1 argument fits. For the patient with arthritic knees and obesity, the cost to act may not be laziness. It may be pain.

The verdict on the GLP-1 knee claim

Metzl’s prediction is plausible. Not guaranteed, not ready to become a cheerful pharma commercial with a golden retriever and a pickleball court, but plausible. If GLP-1s keep showing that they reduce weight, reduce pain, and increase activity in patients with knee arthritis and obesity, sports medicine doctors will have a hard time pretending those outcomes belong to some other department.

The catch is that the prescription cannot end at the injection. If the drug reduces pain but nobody helps the patient build strength, restore movement, and find a reason to keep showing up, medicine has only bought a window and left it shut. Metzl, to his credit, is not selling the shot as the finish line. He is selling it as the thing that may get some people to the starting line.

For listeners with bad knees, the concrete stake is simple: the next wave of orthopedic care may not start with a scope or a lecture about willpower. It may start with a weight-loss drug, a walking plan, and a doctor finally admitting that “move more” is useless advice if every step hurts.